Data support the potential of Dupixent to be the first and only targeted medicine to treat bullous pemphigoid, a skin disease with underlying type 2 inflammation; regulatory submissions are under ...

ARCpoint Inc. (TSXV: ARC) (the “Company” or “ARCpoint”) is pleased to announce that it has closed its previously announced non-brokered private placement (the “Offering”) for gross proceeds of ...

Dupixent late-breaking positive pivotal data in bullous pemphigoid presented at AAD . Five times more adults on Dupixent achieved sustained disease remission at 36 weeks compared ...

About Kestra Kestra Medical Technologies, Ltd. is a commercial-stage wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using ...

Vaccinex intends to file a Form 25 with the Securities and Exchange Commission on or about March 17, 2025 to remove its Common Stock from listing on Nasdaq.

First-ever HPV16-positive head and neck cancer Phase 3 clinical trial. PRINCETON, N.J., March 07, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Bio ...

THE WOODLANDS, Texas, March 07, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will participate in a fireside chat at the Leerink ...

Launch Diagnostics delivered audited revenues of £17.9 million and profit after tax of £0.38 million in the year ended 31 December 2023 and has traded in line with the Board’s expectations during the ...

BioNexus Gene Lab Corp. (NASDAQ: BGLC), a technology company dedicated to innovation in the digital and healthcare space, has announced a strategic partnership with ML Tech to optimize the BGLC’s ...

ICU Medical (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced that Company management will participate in a fireside chat at the KeyBanc ...

Vesting of the stock option is subject to such employee's continued service to Taysha on each vesting date. About Taysha Gene Therapies Taysha Gene Therapies (Nasdaq: TSHA) is a clinical-stage ...

ALK ( ALKB:DC / OMX: ALK B) today announced that Health Canada has approved ALK’s ACARIZAX ® tablet for use in children, aged five to 11, with house dust mite (HDM) allergy. ACARIZAX ® is now ...